Lyn kinase functions as a regulator of imatinib sensitivity in CML cells through an unknown mechanism. In patients that fail imatinib therapy but have no detectable BCR-ABL kinase mutation we detected persistently activated Lyn kinase. In imatinib resistant CML cells and patients, Lyn activation is BCR-ABL independent, it is complexed with the Gab2 and c-Cbl adapter/scaffold proteins, and it mediates persistent Gab2 and BCR-ABL tyrosine phosphorylation in the presence or absence of imatinib. Lyn silencing or inhibition is necessary to suppress Gab2 and BCR-ABL phosphorylation and to recover imatinib activity. Lyn also negatively regulates c-Cbl stability while c-Cbl tyrosine phosphorylation is mediated by BCR-ABL. These results suggest that Lyn exists as a component of the BCR-ABL signaling complex and in cells with high Lyn expression or activation, BCR-ABL kinase inhibition alone (imatinib) is not sufficient to fully disengage BCR-ABL mediated signaling and suggests that BCR-ABL and Lyn kinase inhibition are needed to prevent or treat this form of imatinib resistance.
INTRODUCTION
BCR-ABL is a constitutively active tyrosine kinase expressed as a consequence of 9:22 chromosomal translocation (Philadelphia Chromosome) in a majority of chronic myelogenous leukemia (CML) patients and a subset of patients with acute lymphocytic leukemia (ALL) (1).
The role for BCR-ABL in these diseases has been well established by both molecular and animal models (2) and is the basis for target specific therapy by the tyrosine kinase inhibitor, imatinib were isolated from blood samples by density centrifugation (Ficoll-Hypaque), washed with PBS and aliquots were lysed immediately (for RNA extraction) or resuspended in cell culture media (RPMI-1640, 10% fetal bovine serum) and incubated overnight at 37 o C in a 5% CO 2 incubator before treatment with tyrosine kinase inhibitors.
Analysis of BCR-ABL Mutations -BCR-ABL mutations were analyzed in CML patient specimens as previously described (7, 8) . In brief, total RNA was extracted (RNeasy Protect Mini Kit; Qiagen) and used to prime a one-step RT-PCR reaction (Invitrogen) using the following primers: CM10 (5′-GAAGCTTCTCCCTGACATCCGT-3′, BCR: 2609-2630) and 3′ ABL KD (5′GCCAGGCTCTCGGGTGCAGTCC-3′, ABL: 1292-1271), resulting in a 1.3kb fragment. The 1.3kb gel-purified fragment was used as a template to prime a second PCR reaction [5′ ABL KD (5′GCGCAACAAGCCCACTGTCTATGG-3′) and 3′ ABL KD] resulting in amplification of the ABL kinase domain. Second PCR reactions were performed using PCR SuperMix High Fidelity (Invitrogen, Cat. #: 10790-020). The resultant 0.6 kb fragment was isolated by QIAquick Gel Extraction Kit (Cat. #: 28704) and subcloned into the pGEM-T vector (Promega, Cat #: A3600).
At least 10 clones containing the ABL kinase domain were directly sequenced using an ABI377 automated sequencer. 
Transfection
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Twenty-four hours after transfection, cells were harvested or treated with tyrosine kinase inhibitor for 1 h before preparation and analysis of cell lysates.
Lyn cDNA (EcoR1 digest of the pcDNA3.1-Lyn expression vector) was also sub-cloned into the EcoR1 site of the pMX-IRES-GFP vector modified to include a puromycin selection marker (28,29). The pMX-Lyn-IRES-GFP construct (pMX-Lyn) or an empty vector (pMX) (5 µg) was electroporated into freshly washed 2.5 x 10 6 K562 cells in solution T on a setting of 017, according to the manufacturer's (AMAXA, Gaithersburg, MD) instructions. Two days after electroporation, cells were cultured in 10 µg/ml puromycin and sorted for GFP positivity (after 5 days) by flow cytometry (FACS). Empty vector-derived GFP positive cells and GFP positive cells from pMX-Lyn transfectants were examined for Lyn expression and c-Cbl protein levels after 48 hours of growth in the absence of puromycin.
Lyn, Gab2, c-Cbl and BCR-ABL silencing with short interfering RNA (siRNA) -K562 and K562R cells were electroporated with 100 nM siRNA against Lyn, Gab2, c-Cbl or a scrambled control sequence using the AMAXA nucleoporation system (Gaithersburg, MD). All siRNA was purchased from DHARMACON (Lafayette, CO), except BCR-ABL siRNA which was custom designed and synthesized as previously described (30, 31) . Electroporation was performed with freshly washed 2.5 x 10 6 cells in solution T on a setting of 017, according to the manufacturer's (AMAXA) instructions; ~50 % of cells are electroporated under these conditions. Forty-eight to 72 hours after electroporation lysates were prepared and analyzed for effects on protein expression, signaling, caspase activation or cell survival (trypan blue exclusion or MTT assays as described in ref. 31).
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RESULTS

Lyn alters imatinib-mediated phosphoregulation
Previously we reported that Lyn kinase expression and activation are increased as CML cells transition to an imatinib resistant phenotype (19) and similar observations have been reported by other laboratories (20,21). More recent studies suggest that Lyn activation is BCR-ABL independent in some models of leukemogenesis (32). As shown in figure 1, Lyn expression was elevated (>8-fold) in imatinib resistant (K562R) versus imatinib sensitive (K562) cells (inset) and sensitivity to kinase inhibition was distinct in these populations. Hck is not expressed in K562 or K562R cells (data not shown) and screening for elevated or differential expression of additional SFKs (Src, Yes, Fyn) detected only minor changes.
To examine the role of Lyn in CML cell signaling and survival its activation and expression were reduced by Lyn/BCR-ABL kinase inhibitor (dasatinib) or siRNA. Imatinib (figure 1a, left) was unable to suppress the growth or induce apoptosis of Lyn over-expressing K562R cells whereas dasatinib induced growth suppression and apoptosis in both cell lines (figure 1a, right). The effects of these inhibitors on BCR-ABL phosphorylation, Lyn activation and PARP cleavage were compared after short-and long-term incubation (figure 1b). Both BCR-ABL and CrkL phosphorylation were rapidly suppressed by imatinib or dasatinib and both drugs engaged caspase cascades resulting in PARP cleavage (left panel). In K562R cells imatinib suppressed BCR-ABL and CrkL phosphorylation but required 24h incubation to achieve similar levels of kinase suppression as that detected in K562 cells. Lyn kinase was not fully suppressed by imatinib, even after long term incubation whereas dasatinib rapidly suppressed BCR-ABL, CrkL and Lyn phosphorylation, and correlated with activation of PARP cleavage. These results suggest that Lyn activation is not fully inhibited by imatinib in K562R cells and its constitutive In vitro analysis demonstrated that Lyn directs Y177-BCR-ABL phosphorylation that is suppressed by dasatinib, but not imatinib, raising the possibility that Lyn prevents full inactivation of BCR-ABL signaling by retaining critical adaptor protein (Grb2, Gab2) binding sites on BCR-ABL (35-37). Both Y177-BCR-ABL and Gab2 are essential for leukemogenesis (36,38) and earlier reports suggested that Lyn (or other SFK) mediates phosphorylation of both proteins (22-25,39). Some previous studies predicted Gab2 as a direct substrate for BCR-ABL (52), but this conclusion was based on studies of a compound with src/abl inhibitory activity (PD180970). In this study significant changes in the BCR-ABL signaling complexes were noted in cells with high expression of Lyn. For example we noted a direct association of Lyn with Gab2 whose tyrosine phosphorylation is directed by Lyn and not inhibitable by imatinib (figure 
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In this report we note two activities associated with Lyn in CML cells that may relate to its role in imatinib resistance. These include target-specific phospho-regulation (BCR-ABL, 
